SNPX Projected Dividend Yield
Com Par $0.0001/Synaptogenix Inc ( NASDAQ : SNPX )Synaptogenix is a biopharmaceutical company. Co. is focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease (AD), which is in the clinical testing stage. Co. is also evaluating potential therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease, which have undergone pre-clinical testing. Co. has completed an additional analysis in connection with the confirmatory Phase 2 study, which examined moderately severe to severe AD patients treated with Bryostatin-1 in the absence of memantine. 21 YEAR PERFORMANCE RESULTS |
SNPX Dividend History Detail SNPX Dividend News SNPX Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |